Results 161 to 170 of about 44,698 (259)

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Case Report: BKV-specific T cells: a fast, safe and potentially effective treatment option for refractory BKV infections in pediatric patients after allogeneic stem cell transplantation. [PDF]

Front Pediatr
Oberwegner S, Hettler SA, Hensen L, Heinz AT, Braun C, Döring M, Lang P.   +6 more
europepmc   +1 more source

Detecting communities when order and direction matter in social network analysis

Canadian Journal of Statistics, EarlyView.
Abstract A novel algorithm combining both node degree and edge betweenness (node degree+edge betweenness) is developed to highlight gradients in connectivity. It identifies communities within complex directed graphs. These are networks that are composed of actors who have ties that originate and end at themselves (self‐loops).
Benjamin Smith, Tyler Pittman, Wei Xu
wiley   +1 more source

Unveiling trends and clinical progress of immunotherapy for endometrial cancer: a scientometric and clinical trial landscape analysis. [PDF]

Front Immunol
Liu R, Shan W, Hu Z, Wang H, Wang Z, Yang L, Guo R.   +6 more
europepmc   +1 more source

From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities

Cancer Nexus, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling
Xue Zhang, Chongchong Gao, Rui Jiang, Zijian Wu, Jian Bai   +4 more
wiley   +1 more source

High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects. [PDF]

Front Oncol
Liu L, Chen S, Ding M, Duan Y, Pu L, Li L, Peng H, Yu Q.   +7 more
europepmc   +1 more source

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Clinical Pharmacology &Therapeutics, EarlyView.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, Girish S. Gudi, Adam Drake, Maria Pihlgren, Piet H. van der Graaf, Sunitha GN, Andrew Garton, Mario Perro, Cyril Konto, Lida Pacaud   +11 more
wiley   +1 more source

Rewriting microenvironment immunity in glioblastoma. [PDF]

Mol Ther Oncol
Figg JW, Flores CT.
europepmc   +1 more source

Repurposing Registries: Completeness of Real‐World Data for Regulatory and HTA Purposes in Three Cancer‐Focused Registries

Clinical Pharmacology &Therapeutics, EarlyView.
Despite developments in supporting the identification and selection of fit‐for‐purpose registries, a translational gap remains between the original purposes of clinically focused registries and their current and future expected use in policymaking. This study aimed to assess the extent to which cancer‐focused registries collect essential data elements ...
Manon C. Wilpshaar, Doranne Hilarius, Luisa Prada, Ansgar Weltermann, Christine Leopold   +4 more
wiley   +1 more source

Tumor cell ferroptosis in antitumor immunity and immunotherapy efficacy. [PDF]

J Immunother Cancer
Li S, Gajewski T.
europepmc   +1 more source